Provided by Tiger Fintech (Singapore) Pte. Ltd.

Monopar Therapeutics

44.21
+5.3713.83%
Post-market: 44.210.00000.00%19:57 EDT
Volume:34.66K
Turnover:1.44M
Market Cap:272.77M
PE:-14.33
High:44.22
Open:38.80
Low:38.66
Close:38.84
52wk High:54.30
52wk Low:2.29
Shares:6.17M
Float Shares:2.94M
Volume Ratio:0.98
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0842
EPS(LYR):-4.1123
ROE:-59.38%
ROA:-39.12%
PB:5.23
PE(LYR):-10.75

Loading ...

BRIEF-Monopar Announces Abstract Accepted With Distinction For Oral And Poster Presentations At The Upcoming American Neurological Association 2025 Annual Meeting

Reuters
·
Sep 03

Monopar Therapeutics Inc. : Oppenheimer Initiates Coverage With Outperform Rating and Target Price $77

THOMSON REUTERS
·
Sep 03

Monopar Announces Abstract Accepted With Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting

THOMSON REUTERS
·
Sep 03

Raymond James Initiates Monopar Therapeutics at Strong Buy With $80 Price Target

MT Newswires Live
·
Sep 03

BRIEF-Monopar Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million

Reuters
·
Aug 30

Monopar Therapeutics Inc Files for Mixed Shelf of up to $300 Mln - SEC Filing

THOMSON REUTERS
·
Aug 30

Monopar Therapeutics Price Target Maintained With a $74.00/Share by Cantor Fitzgerald

Dow Jones
·
Aug 27

Monopar Therapeutics Coverage Assumed by HC Wainwright & Co. at Buy

Dow Jones
·
Aug 26

Monopar Therapeutics Inc : H.c. Wainwright Assumes Coverage With Buy Rating; Target Price $70

THOMSON REUTERS
·
Aug 26

Monopar Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Aug 14

Monopar Therapeutics Q2 EPS $(0.35) Beats $(0.49) Estimate

Benzinga
·
Aug 12

Monopar Therapeutics: Expects That Its Current Funds Will Be Sufficient to Continue Operations at Least Through December 31, 2026

THOMSON REUTERS
·
Aug 12

Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments

GlobeNewswire
·
Aug 12

Monopar Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview

Reuters
·
Aug 05

CEO Robinson Chandler Reports Disposal of Common Shares in Monopar Therapeutics Inc

Reuters
·
Jul 17

Monopar Therapeutics Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Jul 08